The first mechanisms of resistance to BCR-ABL inhibitors were identified in imatinib-treated CML patients, revealing BCR-ABL gene amplification, or point mutations in the ABL kinase domain that prevented drug binding (Gorre et al., 2001). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.